Mousavi Bentolhoda, Bathaie Seyedeh Zahra, Fadai Farbod, Ashtari Zabihollah, Ali Beigi Neda, Farhang Sara, Hashempour Sara, Shahhamzei Nasim, Heidarzadeh Hamid
Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, P.O.Box: 1985713834, Tehran, Iran.
Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, P.O.Box: 14115-111, Tehran, Iran.
Avicenna J Phytomed. 2015 Sep-Oct;5(5):413-9.
Saffron is the stigma of Crocus sativus L., which has the potentials to play a role in the treatment of many diseases. Although many researches are now going on this precious spice, there are few data on saffron safety in human, especially in patients with chronic mental illnesses. This study aimed to evaluate the short-term safety and tolerability of both saffron and crocin (its major constituent) in adult patients with schizophrenia.
The capsules of saffron aqueous extract (SAE) and crocin were used to evaluate short-term safety and tolerability in patients with schizophrenia. A double-blind, placebo-controlled study was performed on patients with schizophrenia. The patients were all male and were divided into three 22-patient groups. While receiving their normal treatment, they also received a 12 week treatment with SAE (15 mg twice daily), crocin (15 mg twice daily) or placebo.
A total of 61 patients completed the trial; none of them reported a serious side effect. WBC count increased significantly in patients receiving saffron aqua extract (SAE), but it was within the normal range and had no clinical significance. Other hematologic components, markers of thyroid, liver and kidney or inflammation markers had no statistically significant difference among the groups.
This study showed that SAE and crocin in doses of 15 mg twice daily were safely tolerated in patients with schizophrenia.
藏红花是番红花的柱头，具有治疗多种疾病的潜力。尽管目前对这种珍贵香料的研究众多，但关于藏红花对人体安全性的数据，尤其是对慢性精神疾病患者的安全性数据却很少。本研究旨在评估藏红花及其主要成分西红花苷对成年精神分裂症患者的短期安全性和耐受性。
使用藏红花水提取物（SAE）胶囊和西红花苷来评估精神分裂症患者的短期安全性和耐受性。对精神分裂症患者进行了一项双盲、安慰剂对照研究。患者均为男性，分为三个每组22名患者的组。在接受常规治疗的同时，他们还接受了为期12周的SAE（每日两次，每次15毫克）、西红花苷（每日两次，每次15毫克）或安慰剂治疗。
共有61名患者完成了试验；他们均未报告严重副作用。接受藏红花水提取物（SAE）治疗的患者白细胞计数显著增加，但仍在正常范围内，无临床意义。其他血液学成分、甲状腺、肝脏和肾脏标志物或炎症标志物在各组之间无统计学显著差异。
本研究表明, 每日两次服用15毫克剂量的SAE和西红花苷，精神分裂症患者可安全耐受。
